WHG
GLMD icon

Westwood Holdings Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Westwood Holdings Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-26
Closed -$27K – 445
2019
Q4 		$27K Buy
+26
New +$22.3K ﹤0.01% 509

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Westwood Holdings Group's GLMD Position: Q1 2020 in Review

Westwood Holdings Group sold out of Galmed Pharmaceuticals (GLMD) in Q1 2020, closing a stake of 26 shares — an estimated $27K sold.

Westwood Holdings Group first reported a position in GLMD in Q4 2019 and held it in 1 quarter. The position peaked at $27K in Q4 2019. 31 funds tracked by Wall St. Rank hold GLMD as of Q1 2020.

  • Westwood Holdings Group reported no remaining Galmed Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Westwood Holdings Group sold 26 Galmed Pharmaceuticals shares in Q1 2020, an estimated $27K.
  • Westwood Holdings Group first reported a position in Galmed Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Westwood Holdings Group's Galmed Pharmaceuticals position peaked at $27K in Q4 2019.
  • 31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2020.

Based on Westwood Holdings Group's 13F filing for Q1 2020, filed 15 May 2020.